Screener
Axsome Therapeutics AXSM Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $218.38M+45.5% | $191.2M+57.4% | $196M+65.0% | $170.99M+63.2% | $150.04M+72.1% | ||
| $13.56M+0.9% | $14.73M+50.4% | $12.33M+17.3% | $11.91M+41.2% | $13.45M+67.0% | ||
| $204.81M+49.9% | $176.48M+58.0% | $183.67M+69.7% | $159.08M+65.1% | $136.59M+72.7% | ||
| 93.8%+2.8pp | 92.3%+0.4pp | 93.7%+2.6pp | 93%+1.1pp | 91%+0.3pp | ||
| $46.23M-6.7% | $52.68M+17.6% | $48.79M-11.3% | $40.16M-11.5% | $49.54M-0.6% | ||
| $208.14M+59.8% | $185M+53.2% | $169.3M+49.5% | $150.24M+57.2% | $130.28M+25.8% | ||
| $268.02M+43.5% | $254.56M+42.7% | $222.96M+16.5% | $217.1M+29.7% | $186.76M+13.0% | ||
| -$49.65M-35.2% | -$63.36M-11.2% | -$26.96M+62.9% | -$46.11M+26.4% | -$36.71M+53.0% | ||
| -22.7%+1.7pp | -33.1%+13.8pp | -13.8%+47.4pp | -27%+32.8pp | -24.5%+65.1pp | ||
| -$51.19M-4.6% | -$64.54M-8.6% | -$28.13M+62.4% | -$47.23M+26.9% | -$48.93M+38.3% | ||
| $128K+113% | $0— | —— | $0— | -$960K— | ||
| -$51.31M-7.0% | -$64.54M-8.6% | -$28.56M+61.9% | -$47.23M+26.9% | -$47.97M+39.5% | ||
| -23.5%+8.5pp | -33.8%+15.2pp | -14.6%+48.5pp | -27.6%+34.0pp | -32%+59.1pp | ||
| -$0.99-2.1% | -$1.26-3.3% | -$0.55+64.3% | -$0.94+29.9% | -$0.97+41.9% | ||
| -$47.91M-36.9% | -$61.67M-11.6% | -$25.24M+64.4% | -$44.38M+27.1% | -$35.01M+54.1% | ||
| -21.9%+1.4pp | -32.3%+13.2pp | -12.9%+46.8pp | -26%+32.2pp | -23.3%+64.2pp | ||
| -$49.65M-35.2% | -$63.36M-11.2% | -$26.96M+62.9% | -$46.11M+26.4% | -$36.71M+53.0% |
FAQ
- What is Axsome Therapeutics's revenue?
- Axsome Therapeutics (AXSM) generated $776.6M in revenue over the trailing twelve months, up 56.9% year over year.
- Is Axsome Therapeutics profitable?
- Axsome Therapeutics is not currently profitable: it reported a net loss of $191.6M over the trailing twelve months, a -24.7% net margin.
- What are Axsome Therapeutics's profit margins?
- Gross margin is 93.2% and operating margin is -24.0%, with a -24.7% net margin.
- What is Axsome Therapeutics's earnings per share?
- Axsome Therapeutics's diluted EPS over the trailing twelve months is $-3.74.
- Where does Axsome Therapeutics's income statement data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
